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Inﬂuence of Dietary Phytochemicals and Microbiota on Colon Cancer
Risk
Ruth S. MacDonald* and Kelly Wagner
Food Science and Human Nutrition, Iowa State University, Ames, Iowa 50011, United States
ABSTRACT: Colon cancer is the third most commonly diagnosed type of cancer in the United States. Lifestyle and dietary
patterns inﬂuence colon cancer risk both positively and negatively. Among the dietary factors, several plant-derived compounds
have been found to aﬀord colon cancer protection. These compounds potentially inﬂuence all aspects of colonic cellular
regulation and develop complex interrelationships with the colonic microbiome. Increasing understanding of the role of
microorganisms in determining the colonic environment has led to awareness of this important interrelationship among dietary
factors and the microbial population. Plant-derived polyphenols are active mediators of cellular events, target key carcinogenic
pathways, and modulate colonic microbial populations. In turn, the colonic microorganisms metabolize dietary compounds and
mediate cellular events. In addition, the role of estrogen receptors in colon cancer and the importance of dietary components that
mediate estrogen receptor-β are increasingly being discovered. Hence, dietary bioactive compounds and the intestinal microbiota
create a complex milieu that directly aﬀects the carcinogenic events of the colon. These relationships must be carefully
characterized in future research to provide dietary recommendations that will reduce colon cancer risk.
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■ INTRODUCTION
Colon cancer remains the third most commonly diagnosed type
of cancer in the United States, with lung topping the list and
either breast in women or prostate in men, second (NCI
statistics, www.seer.cancer.gov). For 2010, approximately
142,570 men and women were diagnosed with colon cancer,
and about a third will die from the disease, therefore making
this an important health problem. The lifetime risk of
developing colon cancer is around 5% and the average age at
diagnosis is 70. Because of the later age of onset of colon
cancer, and the direct interaction of colonic cells with dietary
components, cancer of the colon is highly responsive to lifestyle
and environmental factors, especially diet.1 In an extensive
review of the epidemiological evidence through 2007, it was
concluded that there was probable evidence that foods
containing dietary ﬁber, garlic, milk, and calcium and limited
suggestive evidence that nonstarchy vegetables, ﬁsh, fruits, and
foods containing folate, selenium, or vitamin D were protective
against colorectal cancers in humans.2 Lifestyle factors have
been correlated with increasing colon cancer risk, including low
physical activity and abdominal fatness. More controversial is
the link between intake of red meat and colon cancer. Large
meta-analyses have found both increased3 or no increased4,5
risk associated with red meat consumption.
The positive link between diet and colon cancer was ﬁrst
recognized over four decades ago when it was observed that
consumption of high amounts of ﬁber by African populations
was associated with low incidence of colon cancer.6 Over the
subsequent years, diets high in dietary ﬁber and whole grains
have been consistently linked with reduced colon cancer risk.7
More recently, protective dietary associations with high
frequency of consumption of fruits and vegetables,8 green
tea,9 and soy10 have also been linked to reduced colon cancer
risk. Because these foods are rich sources of bioactive
phytochemicals, there is active research to identify these
compounds and describe their function in the colon. A partial
list of the most well-studied phytochemicals associated with
reducing colon cancer and proposed mechanisms of action for
dietary compounds is shown in Table 1.
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Table 1. Potential Food Components and Mechanisms for
Reducing Colon Cancer Risk
Potential Cancer Protective Dietary Bioactive Compounds
curcumin Shehzad et al., 201054
epigallocatechin gallate Yang et al., 201197
resveratrol Rimando et al., 200846
quercetin Kyle et al., 201052
genistein Barone et al., 201281
sulforaphane Clarke et al., 200898
lignans Aehle et al., 201194
Potential Anticarcinogenic Mechanisms for Bioactive Compounds
cell growth arrest Davis et al., 201018
induction of apoptosis Pan et al., 201199
inhibition of COX-2 Romagnolo et al., 2011100
regulation of inﬂammation Havenaar et al., 201143
modiﬁcation of microbial population Azcarate-Peril et al., 201139
signaling pathway regulation (e.g., Wnt) Tarapore et al., 201216
epigenetic changes Link et al., 201017
estrogen receptor Gallo et al., 201282
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■ COLON CANCER ETIOLOGY
The etiology of colon cancer has been well studied, and genetic
mutations have been identiﬁed.11 Approximately 15−30% of
colon cancer occurrence is associated with a hereditary
component. Among these, familial adenomatous polyposis
(FAP) is rare, but carriers have an almost 100% risk of
adenocarcinoma. Hereditary nonpolyposis colorectal cancer
(HNPCC) associated with mutation to DNA mismatch repair
genes also correlates with high risk of cancer. Despite these
known genetic factors, the majority of colon cancer cases are
considered to be sporadic and associated with lifestyle or
environmental factors.
Speciﬁc molecular events associated with the progression of
both hereditary and sporadic forms of colon cancer have been
reviewed previously;12 therefore, a full description is beyond
the scope of this review. Brieﬂy, among the ﬁrst changes are in
the adenomatous polyposis coli (APC) gene, which result in
dysregulation of the Wnt pathway. In the intestine, the Wnt
pathway is centrally involved in regulatory aspects of cellular
proliferation and organization.13 The APC protein directly
modulates the transcription factor β-catenin such that when
APC is lost or truncated, β-catenin translocates to the nucleus
and up-reglates transcription of Wnt target genes. Exper-
imentally induced stabilization of Wnt signaling correlates with
dysplasia, cellular overgrowth, and loss of structure.13 It has
been documented that abnormal cellular proliferation within
early cancer lesions, known as aberrant crypt foci (ACF), is
associated with Wnt up-regulation.14 Subsequent mutations
within the intestine ultimately lead to aneuploidy, methylation
of CpG islands, cyclooxygenase-2 (COX-2) activation, and
microsatellite instability. Additionally, tumor growth is
promoted by up-regulated angiogenesis associated with
dysregulation of the Wnt pathway, vascular endothelial growth
factor (VEGF), COX-2, and a wide range of other signaling
systems.15 As a result of the loss of cellular regulation,
adenomatous polyps, or adenoma, arise from the epithelium.
Adenomas are present in about 25% of people over the age of
50 and 50% of those over age 70. Polypectomy, which can be
done during screening colonoscopies, reduces the risk of
cancer. On the basis of the known pathways associated with
colon cancer etiology, ﬁnding dietary components that alter the
Wnt/β-catenin pathway, COX-2, methylation, and micro-
satellite instability would be the most beneﬁcial for cancer
prevention.16,17 Also, dietary factors that inhibit cell prolifer-
ation and angiogenesis and/or induce apoptosis would also be
beneﬁcial.18
■ INFLAMMATORY BOWEL DISEASE AND COLON
CANCER
Ullman et al.19 described the scenario of how inﬂammation in
the colon can lead to cancer. Following an environmental
trigger, a host of events ensue, which create an inﬂammatory
situation in the colonic environment. Enhanced production of
reactive oxygen and nitrogen species, presumably from the
innate and adaptive immune systems, may lead to damage to
DNA, RNA, proteins, and lipids. An important mediator in this
process may be TNF-α, which is released from activated
macrophages and T cells and binds to the TNF-receptor. TNF-
α has been associated with promotion of DNA damage,
inducing angiogenesis, and induction of COX-2.20 TNF-α
activates NF-κB, a transcription factor, and NF-κB can also be
activated by bacteria in the colon, presumably via the Toll-like
receptors.21,22 Activation of NF-κB in immune cells leads to
increase release of cytokines including IL-6, which, through
binding to IL-6-receptors, initiates signaling pathways19,23
leading to inﬂammation. The important role of inﬂammation
in colon cancer development has been documented from both
human studies and animal models.24,25
Recently, the number of Americans who have been
diagnosed with inﬂammatory bowel disease (IBD), which is
the umbrella term for colitis and Crohn’s disease, has increased
signiﬁcantly.26,27 Patients with IBD have an elevated risk of
colon cancer, which is compounded by the length of time with
the disease and its severity.28 In animal studies, inﬂamed
mucosal cells are more likely to progress to cancer.29 The
mechanisms through which inﬂammation in the colon
progresses to cancer are not fully understood; however, it has
been proposed that hypermethylation of tumor suppressors and
DNA mismatch repair genes are likely early events.30 Several
years ago it was clearly shown that anti-inﬂammatory drugs
such as aspirin31 and those that inhibit COX-232 were
protective against colon cancer in humans. Hence, a major
focus of research is to understand these inﬂammatory pathways
and to ﬁnd dietary components that protect and reduce
inﬂammation.
■ COLONIC MICROBIOTA AND COLON CANCER
Notable in the development of colon cancer is the intimate
involvement of colonic microbiota. The intestinal tract is the
largest source of microorganisms in the body. The entire
intestinal tract harbors microorganisms, but the population
density occurs along a gradient, with the stomach containing
103; the jejunum, 106; the terminal ileum, 109; and the colon,
around 1011 microorganisms per gram of intestinal content.33,34
It has been estimated that humans have over 1000 diﬀerent
bacterial species in the gastrointestinal (GI) tract, most of
which have never been fully characterized. A phylogenetic
analysis of microorganisms from 107 samples of human colon
found that the majority of bacterial sequences were associated
with the same four phyla of bacteria: Firmicutes, Bacterioidetes,
Actinobacteria, and Proteobacteria.35 This was consistent
among patients with IBD and controls. The relative ratios of
these bacteria phyla diﬀer between the colon and small
intestine. Studies have found diﬀerences among patients with
and without colorectal cancer in the population of bacteria
phyla.36 Some phyla are increased, whereas others are
decreased. Exactly how these changes aﬀect the cancer process,
however, is not clear.
The microﬂora of the colon contributes signiﬁcantly to the
colonic environment. Microorganisms produce, digest, and
metabolize colonic compounds, which inﬂuences their
bioavailability; they compete for nutrients with each other;
they communicate with the colonic mucosa to sense changes in
the colonic environment and mediate the immune system; and
they secrete a host of enzymes and other compounds.37 For
example, colonic microorganisms may provide the β-glucur-
onidase enzymes that generate carcinogenic metabolites from
compounds consumed in the diet. It has been reported that
patients with colorectal cancer (CRC) have higher β-
glucuronidase activity in fecal samples compared to noncancer
patients.38 In several animal models of IBD, speciﬁc bacteria
have been found to be essential for developing inﬂammation
and cancer, and in a sterile colon neither of these pathologies
develops.39 Thus, colonic microorganisms clearly are involved
in the carcinogenic process. They provide protective roles
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including creating a barrier to reduce interaction of toxins with
the mucosal layer and induce IgA and IL10, which act as anti-
inﬂammatory agents.40 On the negative side, however, some
intestinal microbes may act to promote cancer by inducing pro-
inﬂammatory agents such as reactive oxygen species (ROS), IL-
6, IL-17, and TNF-α.35
■ DIETARY BIOACTIVES AND COLONIC
MICROBIOTA
The interaction between diet and the intestinal microﬂora
directly aﬀects the risk of colon cancer (Figure 1). For example,
when a high-fat diet is consumed, more bile acids are present in
the colon, which can be acted upon by 7α-hydroxylating
bacteria to produce secondary bile acids, such as deoxycholic
acid and lithocholic acid, which are known to be mutagenic.41 A
high-meat diet, which provides sulfur amino acids, may
contribute to promoting the growth of sulfur-reducing
bacteria.42 These produce hydrogen sulﬁde, a toxic compound
that generates free radicals, impairs cytochrome oxidase,
inhibits mucus synthesis and suppresses DNA methylation,
thereby increasing the risk of cancer. Fermentable compounds
in the colon also generate hydrogen, which is used by methane-
producing bacteria to produce methane. The role of
methanogenic bacteria in colon cancer is not well described
but does not seem to be strongly linked.43 However, the
beneﬁcial eﬀects of short-chain fatty acids (SCFA) on colon
health has been well documented.43 Butyrate and propionate
likely enhance the defense mechanisms of the colon and
intestinal motility. In cultured cells, buytrate induces apoptosis,
decreases NF-κB, and blocks histone hyperacetylation, which
induces tumor cell growth arrest.
Among plant foods, phenolic compounds are ubiquitous and
are especially high in coﬀee, tea, berries, nuts, vegetables, and
cereals. Because plant phenolics are poorly absorbed, they may
accumulate in the colon up to the millimolar range and become
subjected to conversion by microorganisms into metabolites
with potential biological activity. Phenolic compounds in the
colon have been found to alter the microbial population by
suppressing the growth of Clostridiium and Bacteroides
species.44 These compounds also may have direct eﬀects on
cancer-related events in the colon. The stilbene resveratrol has
received signiﬁcant attention relative to colon cancer.45 The
anti-inﬂammatory activity of resveratrol includes inhibition of
pro-inﬂammatory mediators, modiﬁcation of eicosanoid syn-
thesis, and inhibition of enzymes including COX-2, NF-κB, and
AP-1, and TNF-α, IL6, and VEGF. Rimando et al.46
summarized studies of resveratrol in animal models of colon
cancer. Most studies showed inhibition of chemically induced
ACF in the colons of mice when resveratrol was given orally.
However, the form of resveratrol is critically important. When
transgenic alfalfa containing resveratrol glucoside was fed to
mice, no inhibition of ACF was observed; however, when the
diet contained the aglycone ACF, the number was reduced,47
which suggests the glucoside may not be eﬀective, and further
illustrates the need to understand bioavailability and interaction
with intestinal microorganisms. In cell culture, several phenolic
compounds inhibit COX-2 activity, presumably by binding to
the enzyme.48 Whether the concentration of these compounds
can be suﬃciently achieved in human diets to aﬀect these
pathways is not known.
Coﬀee is a rich source of phenolic compounds, including
caﬀeic and chlorogenic acids. Kang et al.49 recently reported
that coﬀee and caﬀeic acid speciﬁcally inhibited colon cancer
metastasis in mice and neoplastic cell transformation by
inhibiting MEK1 and TOPK and phosphorylation of ERKs.
They also showed in histology samples from colon cancer
patients that pERK was decreased in patients who consumed
one or more cups of either regular or decaﬀeinated coﬀee. This
suggests that phenolic compounds may have more speciﬁc
eﬀects and that these compounds may bind directly to target
molecules, hence providing new potential therapeutic strategies.
Several animal and cell culture studies have shown that tea-
derived catechins, such as epigallocatechin-3-gallate (EGCG),
possess anticancer activity and mediate many cellular events
that could be protective against cancer.9,50 However, a meta-
analysis of 13 human studies found a slight increase in colon
cancer risk associated with tea consumption in persons
consuming about four cups of tea per day.51 The study could
not distinguish the type of tea consumed. It was proposed by
the authors that although tea does contain antioxidant
compounds such as the catechins, other components of tea
may be procarcinogenic, including nitrosamines and hetero-
cyclic aromatic amines and tannins. Non-tea ﬂavonoids,
speciﬁcally quercetin, were suggested to provide colon cancer
protection.52 Fruits such as apples and vegetables including
Figure 1. Dietary components including prebiotics and probiotics
traverse the digestive process and enter the colon lumen. In the colon,
complex interactions arise between the nondigested components
(some of which function as prebiotics) and the bacteria (commensal as
well as dietary) in the lumen, leading to production of metabolites that
directly inﬂuence both cellular (left) and biochemical (right) events
within the colonic mucosa. The balance of these events determines the
risk for developing colon cancer.
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onions are good sources of quercetin. Quercetin has been
found to have anticancer eﬀects including inhibition of cell
proliferation and induction of apoptosis and inhibition of
Cyp1A and EGFR.53
Probably the most promising phytochemical in cancer
prevention research is curcumin.54 Curcumin, derived from
Curcuma longa, a member of the ginger family, has been a
component of Ayurvedic practice for centuries. Many
anticancer activities have been found for curcumin, including
apoptotic, antiproliferative, antioxidant, and antiangiogenic
properties, which make it a promising cancer therapeutic
compound.54 In an intervention study,55 smokers with clinically
detected ACF were given 2 or 4 g of curcumin orally per day
for 30 days. Curcumin did not aﬀect PGE2 or 5-HETE, in ACF
or normal mucosa, and did not reduce Ki-67 in normal mucosa.
However, the higher dose was associated with a 40% reduction
in ACF number. The subjects receiving the high dose also had a
signiﬁcant increase in curcumin in their blood, thereby
suggesting that curcumin conjugates delivered systemically
may have contributed to the protective eﬀect. It has been
reported that curcumin can bind to the vitamin D receptor and
activate VDR target genes such as CYP3A4, CYP24, and
TRPV6 in Caco-2 cells, which may be another mechanism of
action for curcumin.56 Because curcumin has been found to
mediate many important cancer pathways, clinical trials for
curcumin and cancer are currently underway.54
■ PROBIOTICS, PREBIOTICS, AND COLON CANCER
With the realization of the importance of microorganisms in the
intestine, there has been substantial interest in ﬁnding beneﬁcial
microbes that will enhance health and prevent inﬂammation
and cancer.33 The terms prebiotic, probiotic, and synbiotic have
been recently deﬁned57 (Table 2). The most studied probiotics
have been strains of both Lactobacillus and Biﬁdobacteria.
Probiotic species of Lactobacillus include L. rhamnosus, L.
acidophilus, L. plantarum, L. paracasei, and L. casei; those of
Bif idobacterium include B. infantis, B. animalis, B. longum, and B.
biﬁdum. Some other probiotics include Eschericia coli strain
Nissle 1917 and Saccharomyces boulardii, among others. In a
recent meta-analysis, the role of probiotics in alleviating the
symptoms of irritable bowel syndrome was found to be
generally positive.58 A wide range of biological responses,
including inﬂuencing cell cycle and apoptosis, inhibition of
enzymes, modifying immune factors, and activation of mucosal
barrier components such as defensins, mucins, and trefoil
factors, have been associated with probiotics.59,60 Evidence that
probiotics are beneﬁcial for human colon cancer is limited at
this time;39 however, animal studies have shown promising
eﬀects.61 Lactic acid bacteria have been shown to induce
apoptosis and reduce hydrogen peroxide concentration in the
colon as possible mechanisms that reduce colon cancer risk,62
but it is not clear if commercially marketed probiotic products
have any real eﬃcacy.63 Currently, characterization of the
intestinal microbiome is underway, and this work should lead to
improved understanding of these bacteria and how they change
with diet and disease.
Intestinal microorganisms are in constant ﬂux depending
upon the colonic environment. A major factor contributing to
the relationship between host and microﬂora is the presence of
prebiotics.63 Prebiotics have been found to generate saccha-
rolytic activity in the colon with SCFA as a primary product.64
Prebiotics can lead to enhanced growth and/or survivability of
selected microorganisms, which promotes changes in the
overall microbial population. These changes could be protective
if beneﬁcial bacteria out-compete pathogenic ones, but the
opposite may also occur. Inulin, a term that covers all β(2-1)
linear fructans, is a well-characterized prebiotic.65 Inulin
stimulates colonic production of SCFA, favors the growth of
Lactobacilli and Bif idobacteria, and is associated with reduced
mucosal inﬂammation and lesion scores in a rat model of
IBD.66 Providing probiotics with selective fermentable
substrates that support their growth (i.e., synbiotics) has been
found to produce greater health impacts than either alone.67,68
Prebiotics such as nondigestible carbohydrates (e.g., galacto-
oligosaccharides (GOS), fructo-oligosaccharides (FOS), resist-
ant starch, polydextrose, and inulin), dietary ﬁbers, and
conjugated fatty acids have also been investigated for their
role in IBD.69 In a European study, SYNCAN, a probiotic
mixture of Lactobacillus rhamnosus GG (LGG) and B. lactis
Bbl2 along with the prebiotic oligofructose-enriched inulin was
administered to patients who had undergone a polypectomy or
been diagnosed with CRC.70 After 12 weeks, fecal water from
the subjects given the synbiotic treatment was found to have
reduced DNA-damaging capacity and colon biopsy tissue
showed reduced DNA damage compared to the placebo-treated
subjects.71 This study demonstrated a protective eﬀect of the
synbiotic treatment on biomarkers of colon cancer in humans.
However, few systematic assessments, using a deﬁned
mechanistic approach, have been done to characterize the
relationships between pre- and probiotics on colon cancer risk.
It is clearly evident that pre- and probiotics have potential to
aﬀect colonic inﬂammation and cancer risk, but only by
characterizing these relationships will there be development of
eﬀective applications for patients.
The barrier function of the colon is critical as the ﬁrst line of
defense. Within the colon, the mucus layer provides the barrier
for the underlying mucosal cells to inﬂammatory agents in the
lumen. The barrier is composed of a variety of compounds,
including mucus, which forms a physical deterrent to pathogens
and antigens.72 Within the mucus are a variety of compounds
with speciﬁc protective functions, such as the mucins (MUC1,
2, 3, and 4) and trefoil factors (TFF 1, 2, and 3), which are
secreted by goblet cells. In a rat model of colitis, feeding
probiotics FOS and resistant starch individually were found to
increase MUC2 in colon, but when fed together the eﬀect was
signiﬁcantly greater.73 Dietary proteins are not typically
considered true prebiotics; however, there is some evidence
that some proteins may provide direct or synergistic eﬀects on
colonic barrier function.74 Spray-dried porcine plasma fed to
weaning pigs provided enhanced colonic barrier and reduced
inﬂammation.75 Whey protein has been found to promote LGG
survival in the human colon76 and to protect rats from dextran
sodium sulfate (DSS) induced inﬂammation.77 These studies
suggest that proteins may play a role as prebiotics for some
Table 2. Deﬁnitions of Probiotics, Prebiotics, and
Synbiotics57
probiotic: live microorganisms that, when administered in adequate amounts,
confer a beneﬁcial health eﬀect on the host
prebiotic: food ingredients that cannot be digested by the human digestive
system but are metabolized by discrete enteric microbes, thus stimulating
proliferation of selected gastrointestinal (GI) bacteria species thought to be
beneﬁcial for human health
synbiotic: supplement composed of a mixture of probiotics and prebiotics
aimed at enhancing survival and colonization of the supplemented species in
the GI tract
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probiotics, thereby creating a synbiotic relationship. In a recent
study, casein, whey, and soy protein were fed to mice either
with or without LGG to determine if these dietary components
provided synbiotic interactions. Of the three proteins fed, only
whey resulted in a high level of LGG in the cecum of the mice,
which suggests a protective role of whey protein on the survival
of the probiotic through the digestion process. Mice treated
with DSS had increased MUC1 expression in the colon when
fed casein, regardless of LGG treatment. MUC1 expression was
also increased by DSS in mice fed whey without LGG but was
not increased when LGG was fed, suggesting a protective eﬀect
of the probiotic on MUC1. Mice fed soy and treated with DSS
had MUC1 expression levels similar to those fed casein without
DSS, regardless of LGG. Overall, the mice fed soy and treated
with DSS had barrier protein expression similar to that of the
casein-fed mice not treated with DSS, thereby suggesting a
protective eﬀect of soy protein independent of the probiotic.
Soy components, such as lunasin,78 ﬁber,79 and isoﬂavones,80
have been found to reduce inﬂammation and cancer in animal
models. This and other studies clearly demonstrate that diet
composition aﬀects probiotic survival, that a wide variety of
food components may inﬂuence colonic barrier function, and
that future work needs to thoughtfully incorporate the
interconnectedness of the colonic microbiome with diet and
the disease process.
■ ESTROGENIC BIOACTIVES AND COLON CANCER
A current interest in colon cancer regulation is the role of
estrogen.81,82 Estrogen and the estrogen receptors ERα and
ERβ mediate a plethora of biological responses and participate
in the initiation and progression of cancers.83 Several dietary
bioactive compounds directly interact with the estrogen
receptors. The response of a given cell to estrogen activation
is dependent upon the relative proportion of the two subtypes
and downstream regulators. The most well-deﬁned events
associated with estrogen receptors are the genomic responses in
which activation of the ligand-binding domain leads to
conformational change in the receptors, nuclear translocation,
and binding to estrogen response elements on DNA. However,
many eﬀects of estrogen can have a more rapid onset. These
events, presumably mediated by membrane-tethered receptors,
signal cell proliferation (ERα) or antiproliferation (ERβ).84
Within cancer cells there is substantial evidence that the
nongenomic regulation of cell cycle events by estrogens is
important. Although colon cancer is common in both men and
women, an early hypothesis suggested the incidence of colon
cancer in premenopausal women was actually lower than in
age-matched men.85 After menopause, this diﬀerence dis-
appears, and because colon cancer is more common in older
adults, the link with estrogen was not as obvious. However,
over the past decade there has been growing evidence that ERβ
is a dominant factor in the colon, with expression throughout
the intestinal tract.86,87 From studies of colon tumors and in
cultured cells, it has been shown that the loss of ERβ is
associated with uncontrolled cell growth, failure in cell
diﬀerentiation, and decreased apoptosis.88,89 For these reasons
ERβ is now a prime target for colon cancer therapy, as are
compounds that interact with ERβ.90
Phytoestrogens in the diet have been proposed to play a role
in colon cancer.80 Using ERαKO mice, it has been shown that
the phytoestrogen genistein, derived from soy, altered colon
cancer progression, presumably through ERβ. Genistein is the
most abundant phytoestrogen in soy and is structurally similar
to 17β-estradiol. Two other phytoestrogens, daidzein and
glycitein, are also present in soy and have weak estrogenic
activity. Several studies have demonstrated that phytoestrogens
such as genistein91 or ERβ-speciﬁc antagonists92 mediate colon
cancer. Acting as a selective estrogen receptor modulator,
resveratrol may also aﬀect colon cancer via the estrogen
receptor.90 Using in vitro assays,93 it was found that quercetin
binds to ERα as an estradiol antagonist and also binds to ERβ,
leading to apoptosis. Dietary lignans, found in whole grains,
have also been found to possess estrogenic activity, which may
be one mechanism through which these foods reduce colon
cancer risk.94 It is not fully clear whether these phytoestrogen
Figure 2. Simpliﬁed model of ERβ regulation of tumor cell growth.83 Phytoestrogens bind to either the membrane-tethered receptors, which are
associated with transcription factors SP-1 and AP-1, or nuclear receptors, which are associated with heat shock proteins (HSP). Activation of the
membrane-tethered receptors is associated with rapid signaling, potentially via the p38/MAPK pathway. This leads to antiproliferative and pro-
apoptotic eﬀects. Activation of the nuclear receptor results in recruitment of cofactors that bind to estrogen receptor elements (ERE) on DNA,
thereby modifying gene expression and inducing protein synthesis. The outcome of activation of ERβ in the colon is suppression of carcinogenic
pathways.
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compounds activate the genomic or nongenomic receptors;
however, the role of ERβ in colon cancer is now well
accepted.95 The evidence that ERβ provides a protective eﬀect
against colon cancer is strong, and development of therapies
targeting ERβ is likely.96 However, there is currently no
understanding of how phytoestrogens may interact with the
colonic microbiome. Given the potential for phytochemicals to
selectively interact with this receptor, there is a promising role
for dietary components in colon cancer prevention via this
mechanism (Figure 2). More research is needed to understand
fully the role of ERβ and how phytochemicals modulate its
activity.
In summary, the very important interactions among dietary
components and the intestinal microbiome in mediating colon
cancer risk are now clearly evident. Future research of the role
of dietary components in colon cancer must be carefully
designed to ensure these relationships are fully considered.
There are likely to be many phytochemicals with important
anticancer potential, and curcumin is a prime example that is
now in clinical trials. The role of estrogen receptors, especially
ERβ, in colon cancer is increasingly being understood and
provides another target for dietary bioactive components.
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factor.
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